{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:38:05Z","timestamp":1793957885603,"version":"4.8.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Kidney transplantation with hepatitis C viremic (dHCV+) donors appears safe for recipients without HCV when accompanied by direct acting antiviral (DAA) treatment. However, US programs have been reluctant to embrace this approach due to concern about insurance coverage. While the cost of DAA treatment is currently offset by the reduction in waiting time, increased competition for dHCV+ organs may reduce this advantage. This analysis sought to demonstrate the financial benefit of dHCV+ transplant for third-party health insurers to expand coverage availability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>An economic analysis was developed using a Markov model for 2 decisions: first, to accept a dHCV+ organ versus wait for a dHCV uninfected organ; or second, accept a high kidney donor profile index (KDPI) (&gt;85) organ versus wait for a better quality dHCV+ organ. The analysis used Medicare payments, historical survival data, cost report data, and an estimated cost of DAA of $29\u2009874.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>In the first analysis, using dHCV+ kidneys reduced the cost of end-stage kidney disease care if the wait for a dHCV uninfected organ exceeded 11.5 months. The financial breakeven point differed according to the cost of DAA treatment. In the second analysis, declining a high-KDPI organ in favor of a waiting dHCV+ organ was marginally clinically beneficial if waiting times were &lt;12 months but not cost effective.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>dHCV+ transplant appears to be economically and clinically advantageous compared with waiting for dHCV-uninfected transplant but should not replace high-KDPI transplant when appropriate. Despite the high cost of DAA therapy, health insurers benefit financially from dHCV+ transplant within 1 year.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000001056","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T16:42:58Z","timestamp":1612629778000},"page":"e627","source":"Crossref","is-referenced-by-count":7,"title":["Financial Evaluation of Kidney Transplant With Hepatitis C Viremic Donors to Uninfected Recipients"],"prefix":"10.1097","volume":"6","author":[{"given":"David A.","family":"Axelrod","sequence":"first","affiliation":[{"name":"Department of Surgery, University of Iowa, Iowa City, IA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista L.","family":"Lentine","sequence":"additional","affiliation":[{"name":"Department of Medicine, Saint Louis University, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramji","family":"Balakrishnan","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Iowa, Iowa City, IA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Hsin","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Washington University, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terek","family":"Alhamad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Washington University, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Medicine, Saint Louis University, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertran L.","family":"Kasiske","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hennepin County Medical Center, Minneapolis, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy D.","family":"Bloom","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pennsylvania, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Schnitzler","sequence":"additional","affiliation":[{"name":"Department of Medicine, Saint Louis University, St. Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"issue":"Suppl s1","key":"R1-20231127","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ajt.15672","article-title":"OPTN\/SRTR 2018 annual data report: kidney.","volume":"20","author":"Hart","year":"2020","journal-title":"Am J Transplant"},{"key":"R2-20231127","doi-asserted-by":"crossref","first-page":"e13419","DOI":"10.1111\/ctr.13419","article-title":"Report of National Kidney Foundation consensus conference to decrease kidney discards.","volume":";33","author":"Cooper","year":"2019","journal-title":"Clin Transplant"},{"issue":"Suppl s1","key":"R3-20231127","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/ajt.15679","article-title":"OPTN\/SRTR 2018 annual data report: hepatitis C.","volume":"20","author":"Wang","year":"2020","journal-title":"Am J Transplant"},{"key":"R4-20231127","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.pharmthera.2017.10.009","article-title":"Direct antiviral agents (DAAs)\u2014a new age in the treatment of hepatitis C virus infection.","volume":"183","author":"Spengler","year":"2018","journal-title":"Pharmacol Ther"},{"key":"R5-20231127","first-page":"1105","article-title":"Transplanting HCV-infected kidneys into uninfected recipients.","volume":"377","author":"Goldberg","year":"2017","journal-title":"N Engl J Med"},{"key":"R6-20231127","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial.","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med"},{"key":"R7-20231127","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1111\/ajt.14895","article-title":"The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.","volume":"18","author":"Axelrod","year":"2018","journal-title":"Am J Transplant"},{"key":"R8-20231127","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/ajt.14018","article-title":"The changing financial landscape of renal transplant practice: a national cohort analysis.","volume":"17","author":"Axelrod","year":"2017","journal-title":"Am J Transplant"},{"key":"R9-20231127","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/M18-0749","article-title":"Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial.","volume":"169","author":"Reese","year":"2018","journal-title":"Ann Intern Med"},{"key":"R10-20231127","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.31011","article-title":"Hepatitis C virus NAT-positive solid organ allografts transplanted into hepatitis C virus-negative recipients: a real-world experience.","volume":"72","author":"Kapila","year":"2020","journal-title":"Hepatology"},{"key":"R11-20231127","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/jvh.13042","article-title":"Transplantation of kidneys from HCV viremic donors to HCV viremic recipients followed by early direct acting antiviral therapy without ribavirin.","volume":"26","author":"Kapila","year":"2019","journal-title":"J Viral Hepat"},{"key":"R12-20231127","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/ajt.15355","article-title":"Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States.","volume":"19","author":"Bowring","year":"2019","journal-title":"Am J Transplant"},{"key":"R13-20231127","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/ajt.15664","article-title":"Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients.","volume":"20","author":"Gupta","year":"2020","journal-title":"Am J Transplant"},{"key":"R14-20231127","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/ajt.14929","article-title":"Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients.","volume":"18","author":"Kadatz","year":"2018","journal-title":"Am J Transplant"},{"key":"R15-20231127","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2019.11.005","article-title":"Cost-effectiveness of using kidneys from HCV-viremic donors for transplantation into HCV-uninfected recipients.","volume":"75","author":"Eckman","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"R16-20231127","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1111\/ajt.14381","article-title":"The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation.","volume":"17","author":"Levitsky","year":"2017","journal-title":"Am J Transplant"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T22:02:14Z","timestamp":1701122534000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":16,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001056","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]}}}